HOSPITAL UNIVERSITARIO RUBER
Département
Pontifícia Universidade Católica do Rio Grande do Sul
Porto Alegre, BrasilPublications en collaboration avec des chercheurs de Pontifícia Universidade Católica do Rio Grande do Sul (6)
2022
-
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer
Future Oncology, Vol. 18, Núm. 34, pp. 3801-3813
-
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine, Vol. 387, Núm. 3, pp. 217-226
2020
-
Enhancing global access to cancer medicines
CA Cancer Journal for Clinicians, Vol. 70, Núm. 2, pp. 105-124
-
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet, Vol. 396, Núm. 10265, pp. 1817-1828
2017
-
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy
Breast Cancer Research, Vol. 19, Núm. 1
-
Research needs in breast cancer
Annals of Oncology, Vol. 28, Núm. 2, pp. 208-217